NanoViricides Files to Sell 71,400 Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
NanoViricides files to sell 7.14 shares of common stock for holders
Get Free Real-Time Notifications for Any Stock
Monitor tickers like NNVC with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on NNVC
Wall Street analysts forecast NNVC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNVC is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.050
Low
6.00
Averages
6.00
High
6.00
Current: 1.050
Low
6.00
Averages
6.00
High
6.00
About NNVC
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
Continue Reading
NanoViricides: Fiscal Q3 Earnings Snapshot
Company Financial Performance: NanoViricides Inc. reported a loss of $2.2 million in its fiscal third quarter, equating to a loss of 14 cents per share.
Location and Reporting Source: The company is based in Shelton, Connecticut, and the information was generated by Automated Insights using data from Zacks Investment Research.
Continue Reading